-
Ascendis Pharma NASDAQ:ASND Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.
Location: Hellerup, 2900, Denmark | Website: www.ascendispharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
7.684B
Cash
258.7M
Avg Qtr Burn
-82.52M
Short % of Float
5.67%
Insider Ownership
0.73%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
YORVIPATH® (palopegteriparatide, developed as TransCon PTH) Details Adult hypoparathyroidism | Approved Quarterly sales | |
TransCon hGH Details Adult growth hormone deficiency | BLA Acceptance for review | |
TransCon CNP Details Achondroplasia | Phase 2 Data readout | |
TransCon IL-2 B/y + TLR7/8 Details Solid tumor/s, Cancer | Phase 2 Data readout | |
TransCon hGH/TransCon CNP combination Details Achondroplasia | Phase 2 Data readout | |
TransCon hGH Details Turner syndrome | Phase 2 Data readout | |
TransCon TLR7/8 Agonist +/- pembrolizumab Details Cancer, Solid tumor/s | Phase 2 Data readout | |
TransCon IL-2 B/y Details Cancer, Solid tumor/s | Phase 2 Data readout | |
TransCon CNP Details Achondroplasia | Phase 2 Update |